人類乳突病毒疫苗市場－全球產業規模、佔有率、趨勢、機會與預測，按類型、按疾病、按配銷通路、按地區和競爭細分，2020-2030 年

2024 年全球人類乳突病毒 (HPV) 疫苗市場價值為 83.5 億美元，預計到 2030 年將達到 137.7 億美元，複合年成長率為 8.65%。該市場是全球免疫和癌症預防計劃的基石，隨著人們對 HPV 相關疾病認知的提高和免疫運動的擴大，該市場呈現強勁成長。 HPV 相關疾病盛行率的上升，加上醫療保健投資的增加和全球疫苗接種策略的實施，繼續推動市場需求。世衛組織和全球疫苗免疫聯盟等國際衛生機構的支持進一步加快了疫苗的可近性和接種率。單劑量疫苗方案、性別中立疫苗接種計劃以及用於追蹤和管理的數位健康技術等創新方法的引入，預計將提高全球疫苗覆蓋率，並隨著時間的推移減輕 HPV 誘發癌症的負擔。

關鍵市場促進因素

HPV相關疾病盛行率上升

主要市場挑戰

疫苗成本高且定價受限

主要市場趨勢

擴大性別包容性疫苗接種計劃

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：人類乳突病毒疫苗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按類型（二價、四價、九價）
  • 依疾病（子宮頸癌、陰道癌及外陰癌、肛門癌、口咽癌（頭頸癌）、生殖器疣）
  • 按配銷通路（醫院和零售藥局、政府供應商、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美人類乳突病毒疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲人類乳突病毒疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太人類乳突病毒疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美人類乳突病毒疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲人類乳突病毒疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球人類乳突病毒疫苗市場：SWOT 分析

第 14 章：競爭格局

• Merck & Co., Inc.
• GSK plc.
• Serum Institute of India Pvt. Ltd
• Sanofi
• Pfizer Inc.
• Inovio Pharmaceuticals, Inc
• Walvax Biotechnology Co., Ltd
• Bharat Biotech Ltd
• Johnson & Johnson Services, Inc.
• Moderna, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

The Global Human Papillomavirus (HPV) Vaccine Market was valued at USD 8.35 Billion in 2024 and is projected to reach USD 13.77 Billion by 2030, growing at a CAGR of 8.65%. This market is a cornerstone of global immunization and cancer prevention initiatives, witnessing strong growth propelled by rising awareness of HPV-associated diseases and expanded immunization campaigns. Increased prevalence of HPV-related conditions, coupled with improved healthcare investments and the global implementation of vaccination strategies, continues to drive market demand. Support from international health bodies like WHO and GAVI has further accelerated vaccine accessibility and uptake. The introduction of innovative approaches, such as single-dose vaccine regimens, gender-neutral vaccination programs, and digital health technologies for tracking and administration, is expected to improve global vaccine coverage and reduce the burden of HPV-induced cancers over time.

Key Market Drivers

Rising Prevalence of HPV-Related Diseases

The growing prevalence of HPV-related diseases is a major force driving the expansion of the HPV vaccine market. HPV remains one of the most common sexually transmitted infections worldwide, with current statistics indicating that approximately 10% of women globally are carriers at any given time. This widespread presence results in significant health consequences, including about 620,000 new cancer cases in women and 70,000 in men annually, largely driven by cervical, oropharyngeal, and anal cancers. With cervical cancer alone accounting for nearly 530,000 new diagnoses each year, the burden on public health systems is substantial. The increasing rate of infection has led to greater reliance on vaccination as a preventive measure, particularly in regions with high incidence rates, reinforcing the demand for HPV vaccines across both developed and developing countries.

Key Market Challenges

High Vaccine Cost and Pricing Constraints

The high cost associated with HPV vaccines presents a substantial challenge, particularly in low- and middle-income countries where the disease burden is often highest. Budget limitations within public health systems can restrict large-scale procurement, limiting vaccine access to the broader population. These pricing challenges hinder market penetration and slow down immunization program adoption in resource-constrained areas. Manufacturers and global health agencies are increasingly exploring tiered pricing models and strategic collaborations to improve affordability and expand market reach, yet cost remains a limiting factor for universal vaccine access.

Key Market Trends

Expansion of Gender-Inclusive Vaccination Programs

A notable trend in the HPV vaccine market is the shift toward gender-inclusive vaccination policies. Historically targeted at adolescent girls to prevent cervical cancer, immunization programs are now expanding to include boys and young men in response to growing evidence linking HPV to a broader spectrum of cancers, such as oropharyngeal and anal cancers. This inclusive approach significantly increases the eligible vaccination population and provides a new avenue for manufacturers and healthcare providers to improve coverage rates. Broader demographic targeting enhances the potential for widespread immunity and further supports efforts to reduce the overall incidence of HPV-related diseases globally.

Key Market Players

• Merck & Co., Inc.
• GSK plc.
• Serum Institute of India Pvt. Ltd
• Sanofi
• Pfizer Inc.
• Inovio Pharmaceuticals, Inc
• Walvax Biotechnology Co., Ltd
• Bharat Biotech Ltd
• Johnson & Johnson Services, Inc.
• Moderna, Inc.

Report Scope

In this report, the Global Human Papillomavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Papillomavirus Vaccine Market, By Type:

• Bivalent
• Quadrivalent
• Nonavalent

Human Papillomavirus Vaccine Market, By Disease:

• Cervical Cancer
• Vaginal and Vulvar Cancers
• Anal Cancer
• Oropharyngeal (Head and Neck) Cancers
• Genital Warts

Human Papillomavirus Vaccine Market, By Distribution Channel:

• Hospitals and Retail Pharmacies
• Government Suppliers
• Others

Human Papillomavirus Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Papillomavirus Vaccine Market.

Available Customizations

Global Human Papillomavirus Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human Papillomavirus Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Bivalent, Quadrivalent, Nonavalent)
  • 5.2.2. By Disease (Cervical Cancer, Vaginal and Vulvar Cancers, Anal Cancer, Oropharyngeal (Head and Neck) Cancers, Genital Warts)
  • 5.2.3. By Distribution Channel (Hospitals and Retail Pharmacies, Government Suppliers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Human Papillomavirus Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Papillomavirus Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Human Papillomavirus Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Human Papillomavirus Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By Distribution Channel

7. Europe Human Papillomavirus Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Papillomavirus Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Human Papillomavirus Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Human Papillomavirus Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Human Papillomavirus Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Human Papillomavirus Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Human Papillomavirus Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Papillomavirus Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Human Papillomavirus Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Human Papillomavirus Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Human Papillomavirus Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By Distribution Channel

9. South America Human Papillomavirus Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Human Papillomavirus Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Human Papillomavirus Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human Papillomavirus Vaccine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. GSK plc.
• 14.3. Serum Institute of India Pvt. Ltd
• 14.4. Sanofi
• 14.5. Pfizer Inc.
• 14.6. Inovio Pharmaceuticals, Inc
• 14.7. Walvax Biotechnology Co., Ltd
• 14.8. Bharat Biotech Ltd
• 14.9. Johnson & Johnson Services, Inc.
• 14.10.Moderna, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer